The latest announcement is out from Bausch Health Companies ( (TSE:BHC) ).
Bausch Health Companies Inc. has announced the adoption of a shareholder rights plan (SRP) to ensure fair treatment of all shareholders in the event of any unsolicited take-over bid or acquisition of control. This move is not in response to any specific acquisition proposal but aims to provide the board with the opportunity to explore value-enhancing alternatives. The SRP, which requires acceptance by the Toronto Stock Exchange and ratification by shareholders within six months, is similar to plans adopted by other Canadian public companies.
Spark’s Take on TSE:BHC Stock
According to Spark, TipRanks’ AI Analyst, TSE:BHC is a Neutral.
Bausch Health Companies’ stock is moderately rated mainly due to solid revenue growth and cash flow generation. However, high leverage, negative equity, and profitability issues weigh heavily. Technical indicators show neutral momentum, while valuation is unattractive due to negative earnings. Positive earnings call and corporate events provide some optimism, but financial stability concerns remain prevalent.
To see Spark’s full report on TSE:BHC stock, click here.
More about Bausch Health Companies
Bausch Health Companies Inc. is a global, diversified pharmaceutical company focused on delivering better health care outcomes. The company develops, manufactures, and markets a range of products in areas such as gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health, primarily through its controlling interest in Bausch + Lomb Corporation.
YTD Price Performance: -45.59%
Average Trading Volume: 2,854,116
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.6B
For an in-depth examination of BHC stock, go to TipRanks’ Stock Analysis page.